首页> 外国专利> Methods for predicting acute severe colitis treatment response

Methods for predicting acute severe colitis treatment response

机译:预测急性严重结肠炎治疗反应的方法

摘要

The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.
机译:本发明涉及预测急性严重结肠炎治疗响应的方法。目前,没有药物反应的生物标志物。本发明提供了第一预测工具,用于反应急性严重溃疡性结肠炎中的第一和二线治疗。从患者活组织检查中鉴定了失去的微小RNA的推定mRNA靶。将十五种肠微小RINRASA加上5个生物学值的一个分类器被鉴定为96.6%的预测精度,用于将来自非响应者的响应者判断为类固醇。使用类似的方法,鉴定了基于6和4粘膜微小RORNA的算法,将来自非响应者的响应者分类为英夫利昔单抗和环孢菌素。特别地,本发明涉及通过测量选自HP_HSA-MIR-3934,HP_HSA-MIR-100,HSA-MIR-718,HP_HSA-中选择的几种miRNA的表达水平来预测急性严重性结肠炎治疗响应的方法。 MIR-193B,HSA-MIR-3150A-5P,HP_A-MIR-1260B,HSA-MIR-938,HSA-MIR-518B和HSA-MIR-1468。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号